Implementing the American Academy of Pediatrics Attention-Deficit/ Hyperactivity Disorder Diagnostic Guidelines in Primary Care Settings

2006 ◽  
Vol 2006 ◽  
pp. 358-360
Author(s):  
H.R. Gephart
Keyword(s):  
Primary Care ◽  
Attention Deficit Hyperactivity Disorder ◽  
American Academy ◽  
Attention Deficit ◽  
Hyperactivity Disorder ◽  
Primary Care Settings ◽  
American Academy Of Pediatrics

scholarly journals Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015

2017 ◽  
Vol 132 (6) ◽  
pp. 654-659 ◽  
Author(s):  
Rachel L. Hulkower ◽  
Meghan Kelley ◽  
Lindsay K. Cloud ◽  
Susanna N. Visser
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
American Academy ◽  
Behavior Therapy ◽  
Attention Deficit ◽  
Adhd Medication ◽  
Prior Authorization ◽  
Medication Treatment ◽  
Hyperactivity Disorder ◽  
American Academy Of Pediatrics ◽  
Authorization Policies

Objectives: In 2011, the American Academy of Pediatrics updated its guidelines for the diagnosis and treatment of children with attention-deficit/hyperactivity disorder (ADHD) to recommend that clinicians refer parents of preschoolers (aged 4-5) for training in behavior therapy and subsequently treat with medication if behavior therapy fails to sufficiently improve functioning. Data available from just before the release of the guidelines suggest that fewer than half of preschoolers with ADHD received behavior therapy and about half received medication. About half of those who received medication also received behavior therapy. Prior authorization policies for ADHD medication may guide physicians toward recommended behavior therapy. Characterizing existing prior authorization policies is an important step toward evaluating the impact of these policies on treatment patterns. We inventoried existing prior authorization policies and characterized policy components to inform future evaluation efforts. Methods: A 50-state legal assessment characterized ADHD prior authorization policies in state Medicaid programs. We designed a database to capture data on policy characteristics and authorization criteria, including data on age restrictions and fail-first behavior therapy requirements. Results: In 2015, 27 states had Medicaid policies that prevented approval of pediatric ADHD medication payment without additional provider involvement. Seven states required that prescribers indicate whether nonmedication treatments were considered before Medicaid payment for ADHD medication could be approved. Conclusion: Medicaid policies on ADHD medication treatment are diverse; some policies are tied to the diagnosis and treatment guidelines of the American Academy of Pediatrics. Evaluations are needed to determine if certain policy interventions guide families toward the use of behavior therapy as the first-line ADHD treatment for young children.

scholarly journals Prevalence and Assessment of Attention-Deficit/Hyperactivity Disorder in Primary Care Settings

PEDIATRICS ◽  
2001 ◽  
Vol 107 (3) ◽  
pp. e43-e43 ◽  
Author(s):  
R. T. Brown ◽  
W. S. Freeman ◽  
J. M. Perrin ◽  
M. T. Stein ◽  
R. W. Amler ◽  
...  
Keyword(s):  
Primary Care ◽  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Hyperactivity Disorder ◽  
Primary Care Settings

Training for Success in a Child with ADHD

Biofeedback ◽  
2013 ◽  
Vol 41 (2) ◽  
pp. 75-81
Author(s):  
Lena Santhirasegaram ◽  
Lynda Thompson ◽  
Andrea Reid ◽  
Michael Thompson
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
American Academy ◽  
Attention Deficit ◽  
The Other ◽  
Hyperactivity Disorder ◽  
Randomized Controlled ◽  
American Academy Of Pediatrics ◽  
Randomized Controlled Studies ◽  
Level 1

This article presents a case study to illustrate how children with attention-deficit/hyperactivity disorder (ADHD) can be assessed and successfully trained using neurofeedback. There is established efficacy for using neurofeedback to treat ADHD (Arns, De Ridder, Strehl, Breteler, & Coenen, 2009; Gani, Birbaumer, & Strehl, 2009; Gevensleben et al., 2009). Indeed, the American Academy of Pediatrics gave biofeedback Level 1 efficacy in its 2012 review (American Academy of Pediatrics, 2012), the same level of efficacy as is given to medications. The other condition that has sufficient randomized controlled studies to establish efficacy for electroencephalogram biofeedback is epilepsy (Tan et al., 2009). This case is presented to share techniques that will help clinicians conduct neurofeedback appropriately so that good results are obtained. The future of our field depends on every practitioner doing a quality job with excellent outcomes.

Sign in / Sign up

Export Citation Format

Share Document